Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: Cidara therapeutics | Rare Historical Photos

Merck Just Made a Big Bet on a New Cancer Growth Engine

Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing dividend, and long-term growth.

Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything

Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything

Merck's multi-billion-dollar acquisition of Cidara Therapeutics is a strategic move to secure a new era of growth with a high-potential antiviral asset.

Merck Makes Big Bet On Flu Protection With Cidara Buyout

Merck Makes Big Bet On Flu Protection With Cidara Buyout

Merck Co. Inc. (NYSE:MRK) on Friday agreed to acquire Cidara Therapeutics, Inc. (NASDAQ:CDTX) for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why Is Cidara Therapeutics (CDTX) Stock Trending Overnight?

Cidara Therapeutics Inc. (NASDAQ:CDTX) shares are trending on Friday.

Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive'

JP Morgan initiated coverage of Cidara Therapeutics Inc. (NASDAQ:CDTX) on Friday, citing its lead asset, CD388, for influenza, underscoring the game-changing potential of the product and multi-billion dollar potential in the U.S. alone.

Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage

Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading higher on Friday after the biotech company made a recent announcement about their presentation at the upcoming ESWI 2025 conference. JP Morgan also initiated coverage of the stock, assigning it an Overweight rating and setting a price target of $200.

Are These Biotech Stocks a Buy or Sell for August: Bionano Genomics (BNGO) vs. Cidara Therapeutics (CDTX)?

Underpinned by undeniable growth trends of an aging population, breakthrough therapies, and the inelastic demand for healthcare products and medicines, the biotech industry is expected to perform well in the near term. Given this backdrop, let’s compare two biotech stocks, Bionano Genomics (BNGO) and Cidara Therapeutics (CDTX), to determine if…

inkl

Read news from The Economist, FT, and more,
with one subscription

1

People

Steve Reitmeister

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Bionano Genomics

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

399,328 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play